G-protein-coupled receptors (GPCRs) represent the most extensively validated drug target class in modern pharmacology, targeted by ~34% of FDA-approved medicines. Using AlphaFold2, biologists identifi…
Structural geometry is more conserved through evolutionary drift than primary amino acid sequences.
AlphaFold2 predicted 3D folds directly from divergent genes, revealing the classic seven-transmembrane architecture.
Because GPCRs orchestrate vital cell signaling pathways, newly uncovered allosteric binding sites provide pathways for selective therapeutics.
💡 Core Takeaway: AI structural screening exposes blind spots in even the most thoroughly investigated biological domains.
G-protein-coupled receptors (GPCRs) represent the most extensively validated drug target class in modern pharmacology, targeted by ~34% of FDA-approved medicines. Using AlphaFold2, biologists identified an entirely hidden branch by querying structural topology rather than sequence homology.
This development reshapes competitive dynamics in the sector.
Regulatory frameworks and infrastructure readiness remain critical.
Mainstream adoption expected within 3–5 years.